20 results about "Platelet Numbers" patented technology

The invention discloses application of CD146 + umbilical cord mesenchymal stem cell subpopulation in preparation of drugs for preventing and treating immune thrombocytopenia and a product, and relates to the technical field of biology. The invention provides an application of a CD146 + mesenchymal stem cell subset in preparation of a medicine for treating or preventing immune thrombocytopenia. The CD146 < + > mesenchymal stem cell subpopulation can increase the number of platelets of ITP patients, regulate the CD4 < + > / CD8 < + > ratio of the ITP patients and remarkably reduce the MDSC proportion, so that the in-vivo immune state is changed.

The invention discloses a hematology analyzer and a platelet numerical value measuring method, in the hematology analyzer, an analysis unit is used for receiving a pulse signal to generate a first image, receiving an optical signal to generate a second image, obtaining a platelet original numerical value based on the first image, obtaining an interference coefficient of a leukocyte fragment based on the second image, and obtaining the platelet numerical value based on the interference coefficient; and obtaining a platelet measurement value based on the platelet original value and the interference coefficient. Through the cooperation of the impedance module and the flow fluorescence module, the platelet original value in the blood cell sample and the interference coefficient of the leukocyte fragment are detected, and the accuracy of each step in the calculation process of the platelet measurement value is ensured. Meanwhile, the platelet measurement numerical value is calculated through the analysis unit based on the platelet original numerical value and the interference coefficient, so that the accuracy of the blood cell analyzer for measuring the platelet measurement numerical value is improved, the practicability of the blood cell analyzer is improved, and the use experience of a user on the blood cell analyzer is improved.

This invention discloses the application and method of a STAT1-targeting inhibitor in the treatment of immune thrombocytopenic purpura (ITP). It employs ivermectin, a STAT1 nuclear translocation inhibitor, and fludarabine, a STAT1 activation inhibitor. By injecting either the activation inhibitor or the nuclear translocation inhibitor, the platelet count in a mouse model of ITP is increased. Fludarabine, a fluorinated nucleotide analog of vidarabine, is non-radioactive and a small-molecule phosphorylation inhibitor. Ivermectin is a small-molecule inhibitor of nuclear translocation mediated by α / β1 introgression protein. Both have high bioavailability and are widely used to treat various hematological diseases with good safety profiles. Their application in treating ITP is safe, effective, and shows high compliance.

The invention discloses an application of a natural product WithangatinA in preparation of erythroleukemia induced differentiation treatment drugs, the natural product WithangatinA promotes HEL and K562 cells to be transformed from malignant proliferative cells to normal megakaryocytes by inducing the cell particle size to become larger and significantly increasing multinuclear megakaryocytes and promoting expression of surface labeled molecules differentiated from megakaryocytes at the same time, and the erythroleukemia induced differentiation treatment drugs are obtained. The effect of resisting erythroleukemia is achieved. After the natural product Withangulin A is adopted for treatment, the size and the weight of the spleen of a leukemia mouse can be remarkably reduced, the hematocrit and the platelet number of the mouse are remarkably increased, in addition, treatment of the natural product Withangulin A has no obvious influence on the weight of the mouse, and the safety is high. In-vivo research shows that the medicine can induce megakaryocyte differentiation of erythroleukemia in a mouse body, the effect of resisting erythroleukemia is achieved, and a research basis is provided for development of differentiation treatment medicines of erythroleukemia.

The invention belongs to the technical field of molecular breeding, and particularly relates to a molecular marker related to the number of blood platelets and somatic cell scores of dairy cows and application of the molecular marker. Whole genome re-sequencing and genotype analysis are carried out on 348 Holstein dairy cows, and GWAS and haplotype correlation analysis is combined, so that a haplotype formed by two SNP sites on an NKAIN2 gene at 27230850 bp and 27231227 bp of a ninth chromosome of the dairy cows is found to be remarkably related to the number of platelets and somatic cell scores. The platelet number estimation breeding value of a haplotype GA individual is remarkably lower than that of an AG individual, and the somatic cell score estimation breeding value is remarkably lower than that of the AG individual. The molecular marker provided by the invention can be used for auxiliary screening of dairy cows with relatively low somatic cell scores and suitable platelet levels, improves the disease resistance and production benefits of the dairy cows, and is suitable for molecular marker-assisted breeding.

GABRR1 is shown to be expressed on subsets of hematopoietic stem cells (HSCs) and megakaryocyte progenitors (MkPs). Inhibition of GABRR1 inhibits MkP differentiation and reduction of platelet numbers in blood. Overexpression of GABRR1 or treatment with agonists significantly promotes MkP generation and growth of megakaryocytes.

The invention provides a traditional Chinese medicine composition for treating kidney-yang deficiency type NSAA and application of the traditional Chinese medicine composition, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by mass: 10 to 30 parts of radix rehmanniae preparata, 10 to 15 parts of herba cistanche, 6 to 15 parts of fructus psoraleae, 3 to 15 parts of herba epimedii, 6 to 15 parts of bran rhizoma atractylodis macrocephalae, 5 to 15 parts of fructus lycii, 10 to 15 parts of salted cortex eucommiae and 10 to 30 parts of herba agrimoniae. The traditional Chinese medicine composition is based on conditioning of the whole physical condition of a patient, and the traditional Chinese medicine component formulas coordinate with one another. Clinical curative effect observation shows that the traditional Chinese medicine composition has a remarkable effect on adjuvant treatment of the kidney-yang deficiency type NSAA, and can effectively improve non-severe aplastic anemia patients with fear of cold and cold limbs, soreness and weakness of waist and knees, fatigue and fatigue and the like after being used, increase the quantity of red blood cells, white blood cells and platelets, and improve the curative effect of the NSAA. And the condition of poor control of western medicines is also obviously improved.

The invention belongs to the technical field of microbial engineering, and particularly relates to leuconostoc mesenteroides subsp. Mesenteroides YWN-1 with the effects of benefiting qi, nourishing blood and enhancing immunity and application of the leuconostoc mesenteroides subsp. Mesenteroides YWN-1. The preservation number of the leuconostoc mesenteroides subsp. Mesenteroides YWN-1 is CGMCC No.34608. The leuconostoc mesenteroides subsp. Mesenteroides YWN-1 can significantly improve immune organ thymus and spleen injuries caused by deficiency of qi and blood, increase the number of red blood cells, hemoglobin and platelets of mice with deficiency of qi and blood, and have the efficacy of improving deficiency of both qi and blood. The phagocytic index, the serum hemolysin content, the half hemolysis value and the immune factor IgG and IgM content of mice with low immunity are improved, and the effects of improving immunity and resistance are achieved.

This invention relates to the field of platelet aggregation function detection technology, specifically to a composition, apparatus, and detection method for determining platelet count. The composition provided by this invention for determining platelet count includes the following components: a platelet activator and optical particles, wherein the optical particles are coated with a bioactive material that binds to platelet surface receptors. This invention employs a combination of a platelet activator and optical particles coated with bioactive material that binds to platelet surface receptors. In the presence of a blood sample, platelets activated by the platelet activator aggregate with the optical particles, causing a change in the light signal, thereby enabling the determination of changes in platelet count.

This invention relates to the field of biomedical detection technology, specifically a method for detecting platelet-rich plasma based on biosensors. The method includes: preparing a biosensor interface capable of recognizing platelet surface-specific antigens; applying the sample to be tested to the interface for a specific binding reaction; monitoring signal changes during the reaction process in real time and acquiring raw data; preprocessing the data to obtain a purification response curve; extracting characteristic parameters such as binding rate, equilibrium response value, and dissociation rate constant from the curve; and finally, analyzing the above parameters based on a pre-established quantitative relationship model to simultaneously calculate the platelet concentration and platelet activation index of the sample. This method achieves simultaneous, rapid, and integrated quantitative assessment of platelet quantity and functional activity in platelet-rich plasma.

This invention relates to the use of hydroxysaffron yellow A in the treatment of platelet-related diseases. Specifically, this invention provides a use of hydroxysaffron yellow A for preparing compositions for the prevention and / or treatment of platelet-related diseases. This invention discovers that hydroxysaffron yellow A can reduce platelet count and the ratio of large platelets, as well as inhibit platelet aggregation and agglutination, for the prevention and treatment of diseases associated with elevated platelet counts such as thrombocytosis, diseases associated with elevated large platelet ratios, and diseases associated with platelet activation, thereby preventing and treating platelet-related diseases.

In the platelet AI training and detecting method and device, a blood sample is preprocessed to obtain a microscopic examination sample; the microscopic examination sample is turbid liquid, and platelets are tiled in a single layer; shooting a microscopic examination sample to obtain a microscopic examination sample image; the microscopic examination sample image is processed, and platelets are distinguished according to the cell pixel area; manually labeling platelets to obtain a labeling graph, wherein the labeling graph comprises normal platelets, large platelets and small platelets; and carrying out AI model training by using the annotation graph to obtain a platelet AI feature data set. Identifying the microscopic examination sample image by using an AI identification algorithm, identifying abnormal platelets in the image, and obtaining the formula that the number of abnormal platelets per unit volume is equal to the total number of abnormal platelets / the volume of the blood sample; calculating to obtain a ratio of abnormal platelets to normal platelets, wherein the ratio is equal to NUMS1 / NUMN; or the ratio of abnormal platelets is equal to NUMS1 / (NUMN + NUMS1).

The invention relates to the technical field of biomedicine detection, in particular to a platelet-rich plasma detection method based on a biosensor, which comprises the following steps: preparing a biosensing interface with a recognition function on platelet surface specific antigens; a sample to be detected is applied to the interface for a specific binding reaction; monitoring signal change in the reaction process in real time and acquiring original data; preprocessing the data to obtain a purification response curve; extracting characteristic parameters such as a binding rate, a balance response value and a dissociation rate constant; and finally, based on a pre-established quantitative relation model, analyzing the parameters, and synchronously calculating the platelet concentration value and the platelet activation index of the sample. According to the method, synchronous, rapid and integrated quantitative evaluation on the quantity and functional activity of platelets in the platelet-rich plasma is realized.

The present invention discloses a quality control method for blood cell testing in medical testing, which relates to the technical field of blood cell medical testing. The method includes obtaining the initial number of platelets in a sample to be tested by a resistance method; obtaining a two-dimensional scattering scatter plot of the sample to be tested based on a light scattering method; determining a total light intensity set based on the sum of the side scattered light intensities and the sum of the forward scattered light intensities in the two-dimensional scattering scatter plot; and performing a linear correction or a nonlinear correction on the initial number of platelets based on a preset correction rule. The present invention constructs a correction rule for platelet number based on experimental data of a blood sample set. For the initial number of platelets and the two-dimensional scattering scatter plot obtained by conventional blood testing, the method determines the corresponding light intensity interval and applies the corresponding correction rule to correct the initial number of platelets, thereby ensuring the accuracy of the platelet measurement result.

The application discloses a Lactobacillus rhamnosus GG ferment with the function of promoting the immunity of patients and a preparation method thereof. The ferment is obtained by fermenting a composition by Lactobacillus rhamnosus GG, and the composition comprises the following components in parts by weight: 8-15 parts of full-fat milk powder, 1-4 parts of concentrated milk protein, 2-7 parts of soybean milk powder, 3-13 parts of glucose, 1-4 parts of fructose glucose syrup, 0.2-0.6 parts of yeast beta-glucan and 60-80 parts of water. The Lactobacillus rhamnosus GG ferment with the function of promoting the immunity of patients contains a high concentration of active Lactobacillus rhamnosus GG in particular. After patients who are taking medicine eat the ferment, the number of platelets in the blood of the patients can be significantly increased, so that the immunity of the patients is improved and the recovery of the patients is promoted.

The invention discloses a traditional Chinese medicine composition for treating thrombocytopenia caused by tumor treatment as well as a preparation and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw material medicines: raw astragalus membranaceus, angelica sinensis, pyrrosia lingua, dendrobe, hairyvein agrimony, madder, raw pollen typhae, selaginella tamariscina, fructus forsythiae and cynomorium songaricum. The invention further discloses a preparation of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of drugs for treating thrombocytopenia caused by tumor treatment. Compared with a single tonifying method, the traditional Chinese medicine composition can more accurately improve double obstacles of platelet generation and release, can obviously increase the number of platelets of tumor patients clinically, and is especially suitable for the symptoms of vital qi deficiency, marrow consumption and stasis-toxin intermingled after tumor treatment.

This application provides a molecular marker in the bovine CSAD gene and its application. The molecular marker is one or more of g.26839616 T>C and g.26842339 C>T in the bovine genome. The molecular marker provided in this application, or the substance used to detect single nucleotide polymorphisms in bovine molecular markers, can be used in bovine genetic breeding to increase platelet count in Tibetan improved cattle offspring and solve the hypoxia bottleneck problem faced in the breeding of plateau cattle.

The present application develops a biomarker that better reflects platelet activation in vivo, and provides a method for assisting in grasping the state of platelet activation that can be used for the examination of thrombotic hemostatic diseases, etc. The method for assisting in grasping the state of platelet activation includes: (1) a process of measuring the concentration of soluble CLEC-2 and the number of platelets in a test sample from a test subject; (2) a process of calculating the value of the concentration of soluble CLEC-2 / number of platelets by dividing the concentration of soluble CLEC-2 by the number of platelets; and (3) a process of comparing the value of the concentration of soluble CLEC-2 / number of platelets with the value of the concentration of soluble CLEC-2 / number of platelets obtained using a test sample from a healthy subject, as needed.

The application provides a molecular marker related to sheep immunity traits and application thereof. The application uses a method for detecting a PLEKHH2 gene SNP site of Lake sheep by combining DNA pool sequencing with KASPar technology. A primer is designed according to a PLEKHH2 gene sequence, DNA is extracted from sheep blood, and PCR amplification, DNA sequencing and sequence analysis are carried out, so that a C / G polymorphic site at the 368th position of the amplified fragment is found. Further, KASPar primers are used to detect the polymorphic site of 889 Lake sheep and to establish a least square model, and correlation analysis is carried out on the genotype and immunity trait indexes, so that it is found that the site is significantly related to the platelet count (PLT) and the mean corpuscular hemoglobin concentration (MCHC) of sheep. Through detection of the molecular marker of the application, the application can be used in marker-assisted disease-resistant breeding of sheep and can accelerate the breeding process of sheep.

The invention discloses a CD36 antigen deletion type typing detection plate, a detection method and a detection kit. According to the detection plate provided by the invention, the CD36 antigens of blood platelets and mononuclear cells can be simultaneously detected in the same plate, and the deletion type of the CD36 antigens can be intuitively judged according to the detection result, so that repeated detection is not needed, the overall detection time is shortened, and the detection result can be quickly obtained. Sample pretreatment is not needed, and the requirements for equipment and technicians are low. The detection specificity is good, the accuracy is high, and the reliability is strong. The detection plate provided by the invention can realize large-flux and full-automatic detection, is suitable for batch screening of platelet CD36 deficiency and high-flux detection of a blood sample, defines CD36 antigen expression data of the blood sample or the platelet sample, provides great convenience and feasibility for establishment of a platelet database, and has a wide application prospect. The formation of a platelet database is promoted, and the method has extremely important significance on blood transfusion safety.